Clinical use of PARP inhibitor in recurrent uterine leiomyosarcoma with presence of a somatic BRCA2 mutation.
| Autor: | Shammas N; Obstetrics and Gynecology, Adventist Health White Memorial Medical Center, Los Angeles, CA, USA., Yang T; Obstetrics and Gynecology, Adventist Health White Memorial Medical Center, Los Angeles, CA, USA., Abidi A; Gynecology Oncology, Kaiser Permanente Riverside Medical Center, Riverside, CA, USA., Amneus M; Gynecology Oncology, Kaiser Permanente Panorama City Medical Center, Panorama City, CA, USA., Hodeib M; Gynecology Oncology, Kaiser Permanente Riverside Medical Center, Riverside, CA, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Gynecologic oncology reports [Gynecol Oncol Rep] 2022 Jul 14; Vol. 42, pp. 101044. Date of Electronic Publication: 2022 Jul 14 (Print Publication: 2022). |
| DOI: | 10.1016/j.gore.2022.101044 |
| Abstrakt: | Uterine leiomyosarcoma (uLMS) is an aggressive mesenchymal tumor associated with a poor prognosis. Research demonstrates that PARP inhibitors (PARPi) improve disease-stable survival in patients with somatic BRCA1/2 mutations through the process of synthetic lethality. Therefore, PARPi's may have a role in treating gynecologic malignancies with deleterious BRCA1/2 mutations. This patient is a 50-year-old female with a history of stage IB uterine leiomyosarcoma, complicated by recurrence along the vaginal cuff and metastases to the lungs. A somatic BRCA2 mutation was identified, and the patient was started on Olaparib for treatment of recurrent disease. The patient has now been disease free for two years. We recommend next generation sequencing be performed to identify functional BRCA1/2 loss in uLMS as PARPi may be a potential targeted therapy for uLMS. Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. (© 2022 The Author(s).) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|